Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
Ningbo, CN
Medicalsystem Biotechnology Co., Ltd. is a Chinese company focused on delivering clinical diagnostic solutions. Their comprehensive product line includes a full array of reagents and instruments designed for COVID-19 detection, such as PCR, antibody, and antigen test kits, alongside nucleic acid reagents. Beyond infectious disease diagnostics, the company also supplies advanced medical equipment like automated biochemistry analyzers (complete with their corresponding bio-reagents), hematology analyzers, urine analyzers, and glycated hemoglobin analyzers. Additionally, their offerings extend to Point-of-Care Testing (POCT) devices and cutting-edge chemiluminescence immunoassay analyzers. In addition to its diagnostic product offerings, Medicalsystem also provides healthcare services. Initially established in 2003 as Ningbo Medicalsystem Biotechnology Co., Ltd., the company officially adopted its current name, Medicalsystem Biotechnology Co., Ltd., in January 2017. Its corporate headquarters are situated in Ningbo, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.10% | -3.07% | -9.32% | -11.85% | -12.86% | -7.11% | -11.08% | -24.75% | -56.01% | -66.04% | -30.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%-12.1% Q1'26: +0.5% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-76.1% Q1'26: +10.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+2.0% Q1'26: -20.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-0.1% Q1'26: +6.5% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%-0.1% Q1'26: +4.0% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-0.4% ★ Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.46× ★ Q1'26: 0.60× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
3.14B
est: 3.37B (-6.9%)
|
3.13B
est: 4.37B (-28.2%)
|
| EBITDA |
574.91M
est: 782.40M (-26.5%)
|
-282.19M
est: 1.01B (-127.8%)
|
| EBIT |
424.58M
est: 456.68M (-7.0%)
|
-443.67M
est: 592.17M (-174.9%)
|
| Net Income |
241.17M
|
-559.91M
|
| SGA |
499.59M
est: 429.95M (+16.2%)
|
527.96M
est: 557.52M (-5.3%)
|
| EPS |
0.71
|
-1.63
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-14 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-15 | B+ | 3/5 | 5/5 | 2/5 | 5/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 9.1K | 0.26% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.0K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 449.1K | 0.06% |
| 4 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 721.72 | 0.22% |
| 5 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.2K | 0.22% |
| 6 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.2K | 0.22% |
| 7 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 514.72 | 0.22% |
| 8 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 59.48 | 0.22% |
| 9 | Vanguard Retirement Income ETF Portfolio VRIF.TO | 0.00% | 19.54 | 0.31% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 9.30 | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Huiping Xiong | Deputy GM, Financial Director & Board Secretary | — | female |
| Ji Hua Zou | GM & Non-Independent Director | — | male |
| Liang Fang | Deputy General Manager | — | male |
| Min Shen | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300439.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
